

**07<sup>th</sup> August, 2025**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**BSE Symbol: INNOVACAP**  
**BSE Scrip Code: 544067**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5th Floor  
Plot No. C/1, “G” Block  
Bandra-Kurla Complex  
Bandra (E), Mumbai – 400051  
**NSE Symbol: INNOVACAP**

Dear Sir/Madam,

**Subject: Outcome of the Board Meeting held today i.e. 07<sup>th</sup> August, 2025.**

Pursuant to Regulation 30 (read with Part A of Schedule III) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”), we wish to inform you that the Board of Directors of Innova Captab Limited, at its meeting held today, i.e. on Thursday, 07<sup>th</sup> August, 2025, inter-alia considered the following matters:

**1. Approval of the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended 30<sup>th</sup> June, 2025:**

In terms of Regulation 33 of the Listing Regulations and pursuant to the approval of the Board of Directors of the Company, we are enclosing herewith a copy of the following as **Annexure 1**:

- a. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30<sup>th</sup> June, 2025;
- b. Limited Review Report on the said Unaudited Financial Results (Standalone and Consolidated) received from the Statutory Auditors of the Company.

This financial results shall be made available on the website of the Company viz. <https://www.innovacaptab.com>. The same shall be treated as compliance with Regulations 46 of the SEBI Listing Regulations.

**2. Approval for the purchase of land property**

The Board approved the purchase of land property and discussed the requisite terms and conditions for entering into the agreement. The Company shall further update once the final Sale agreement is executed between the parties.

Accordingly, the details required to be furnished under Regulation 30 of Listing Regulations read with SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November, 2024 issued thereunder shall be intimated to the stock exchange(s) upon occurrence of the event as per the applicable laws and guidelines.

INNOVA CAPTAB LIMITED  
1281/1, Hilltop Industrial Estate, Near EPIP,  
Phase-I, Jharmajri, Baddi, Dist. Solan  
(H.P.)-173205 India.  
Phone: +91-1795-650820



The Board Meeting commenced at 03:30 P.M. (IST) and concluded at 04:35 P.M. (IST).

This is for your information and record.

Thanking you,

Yours faithfully,  
For **Innova Captab Limited**

**Neeharika Shukla**  
**Company Secretary and Compliance Officer**  
**Membership No.: A42724**

**Encl.: As above**

**Limited Review Report on unaudited consolidated financial results of Innova Captab Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****To the Board of Directors of Innova Captab Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Innova Captab Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
  - a. Innova Captab Limited - Parent
  - b. Univentis Medicare Limited - Subsidiary
  - c. Sharon Bio-Medicine Limited - Subsidiary
  - d. Univentis Foundation - Subsidiary
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Limited Review Report (Continued)**

**Innova Captab Limited**

7. We did not review the interim financial information of one Subsidiary included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of ₹ NIL million, total net loss after tax (before consolidation adjustments) of ₹ 0.56 million and total comprehensive loss (before consolidation adjustments) of ₹ 0.56 million, for the quarter ended 30 June 2025, as considered in the Statement. This interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Gaurav Mahajan**

*Partner*

Panchkula

07 August 2025

Membership No.: 507857

UDIN:25507857BMOAKV2169

**INNOVA CAPTAB LIMITED**

Regd Office : 1513, 15th Floor, Satra Plaza CHS Ltd., Plot No. 19 & 20, Sector-19D, Vashi, Navi Mumbai - 400703, Maharashtra, India  
CIN : L24246MH2005PLC150371, Website: www.innovacaptab.com, Email id : investors@innovacaptab.com, T : +91-22-67944000

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2025**

(₹ in million, except for share data unless otherwise stated)

S.No.	Particulars	Quarter ended		Year ended	
		30-Jun-2025	31-Mar-2025	30-Jun-2024	31-Mar-2025
		Unaudited	(Refer Note 5)	Unaudited	Audited
<b>1</b>	<b>INCOME</b>				
	a) Revenue from operations	3,515.42	3,147.41	2,942.70	12,436.76
	b) Other income	44.83	33.80	21.24	120.45
	<b>Total income (1)</b>	<b>3,560.25</b>	<b>3,181.21</b>	<b>2,963.94</b>	<b>12,557.21</b>
<b>2</b>	<b>EXPENSES</b>				
	a) Cost of materials consumed	2,294.44	2,109.28	1,881.18	7,998.23
	b) Purchase of stock-in-trade	50.47	52.95	84.66	392.18
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(137.53)	(182.00)	25.80	(249.44)
	d) Employee benefits expense	390.90	355.16	248.79	1,167.78
	e) Finance cost	28.60	19.52	1.38	24.05
	f) Depreciation and amortisation expense	110.45	98.02	48.54	247.79
	g) Other expenses	396.15	335.17	280.51	1,266.46
	<b>Total expenses (2)</b>	<b>3,133.48</b>	<b>2,788.10</b>	<b>2,570.86</b>	<b>10,847.05</b>
<b>3</b>	<b>Profit before tax (1-2)</b>	<b>426.77</b>	<b>393.11</b>	<b>393.08</b>	<b>1,710.16</b>
<b>4</b>	<b>Tax expense</b>				
	- Current tax	62.75	39.47	56.96	267.78
	- Deferred tax	53.87	57.91	41.35	159.80
	<b>Total tax expense (4)</b>	<b>116.62</b>	<b>97.38</b>	<b>98.31</b>	<b>427.58</b>
<b>5</b>	<b>Profit for the period / year (3-4)</b>	<b>310.15</b>	<b>295.73</b>	<b>294.77</b>	<b>1,282.58</b>
<b>6</b>	<b>Other comprehensive income (OCI)</b>				
	(i) Items that will not be reclassified to profit or loss	0.09	5.72	(1.25)	3.53
	(ii) Income tax related to items that will not be reclassified to profit or loss	(0.05)	(2.00)	0.32	(0.88)
	<b>Total other comprehensive income / (loss) (net of tax) for the period / year (6)</b>	<b>0.04</b>	<b>3.72</b>	<b>(0.93)</b>	<b>2.65</b>
<b>7</b>	<b>Total comprehensive income for the period / year (5+6)</b>	<b>310.19</b>	<b>299.45</b>	<b>293.84</b>	<b>1,285.23</b>
<b>8</b>	<b>Paid-up equity share capital (face value ₹ 10 per share)</b>	<b>572.25</b>	<b>572.25</b>	<b>572.25</b>	<b>572.25</b>
<b>9</b>	<b>Other equity</b>				<b>9,021.92</b>
<b>10</b>	<b>Basic and diluted earnings per equity share in ₹ (not annualised for the quarters)</b>	<b>5.42</b>	<b>5.17</b>	<b>5.15</b>	<b>22.41</b>


See accompanying notes to the unaudited consolidated financial results




**Notes:**

- 1 The above consolidated financial results of Innova Captab Limited ("the Company" or "the Holding Company") and its subsidiaries (Holding and its subsidiaries together referred to as "the Group") have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 ("the act") read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended. The results for the quarter ended 30 June 2025 are available on the Company's website i.e. [www.innovacaptab.com](http://www.innovacaptab.com) under investor information section and on the stock exchange website i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).
- 2 The above consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 07 August 2025. The Board of Directors at their meeting held on 07 August 2025 have approved the above results and taken them on record. The statutory auditors of the Company have expressed an unmodified review conclusion on the consolidated financial results for the quarter ended 30 June 2025.
- 3 The Group comprise the following entities (all of which have been incorporated in India):
  - Innova Captab Limited (Holding Company)
  - Univentis Medicare Limited (Subsidiary Company)
  - Sharon Bio - Medicine Limited (Subsidiary Company)
  - Univentis Foundation (Subsidiary)
- 4 The Group has only one reportable segment i.e. "Drugs and pharmaceutical products" as per Ind-AS 108 "Operating Segments" specified under section 133 of the Companies Act, 2013. Accordingly, the disclosures as per the listing agreement are not applicable to the group.
- 5 The figures of the last quarter ended 31 March 2025, as reported in these consolidated financial results, are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit.

For and on behalf of the Board of Directors of  
Innova Captab Limited



**Vinay Lohariwala**  
Managing Director  
DIN: 00144700



**Lokesh Bhasin**  
Chief Financial Officer

Place: Panchkula  
Date: 07 August 2025



**Limited Review Report on unaudited standalone financial results of Innova Captab Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****To the Board of Directors of Innova Captab Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Innova Captab Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2025 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it



B S R & Co. LLP

**Limited Review Report (Continued)**

**Innova Captab Limited**

contains any material misstatement.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Gaurav Mahajan**

*Partner*

Panchkula

07 August 2025

Membership No.: 507857

UDIN:25507857BMOAKU5243

**INNOVA CAPTAB LIMITED**

Regd Office : 1513, 15th Floor, Satra Plaza CHS Ltd., Plot No. 19 & 20, Sector-19D, Vashi, Navi Mumbai - 400703, Maharashtra, India

CIN : L24246MH2005PLC150371, Website: www.innovacaptab.com, Email id : investors@innovacaptab.com, T : +91-22-67944000

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2025**

(₹ in million, except for share data unless otherwise stated)

S.No.	Particulars	Quarter ended		Year ended	
		30-Jun-2025	31-Mar-2025	30-Jun-2024	31-Mar-2025
		Unaudited	(Refer Note 4)	Unaudited	Audited
<b>1</b>	<b>INCOME</b>				
	a) Revenue from operations	2,869.79	2,425.22	2,268.32	9,580.61
	b) Other income	43.15	43.56	46.43	167.75
	<b>Total income (1)</b>	<b>2,912.94</b>	<b>2,468.78</b>	<b>2,314.75</b>	<b>9,748.36</b>
<b>2</b>	<b>EXPENSES</b>				
	a) Cost of materials consumed	2,034.64	1,874.18	1,698.70	7,155.10
	b) Purchase of stock-in-trade	12.82	2.34	1.38	6.84
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(10.82)	(136.07)	27.81	(113.42)
	d) Employee benefits expense	253.45	213.21	119.55	627.43
	e) Finance cost	27.68	18.69	0.89	21.68
	f) Depreciation and amortisation expense	90.76	78.12	30.55	170.15
	g) Other expenses	231.49	189.76	136.42	681.67
	<b>Total expenses (2)</b>	<b>2,640.02</b>	<b>2,240.23</b>	<b>2,015.30</b>	<b>8,549.45</b>
<b>3</b>	<b>Profit before tax (1-2)</b>	<b>272.92</b>	<b>228.55</b>	<b>299.45</b>	<b>1,198.91</b>
<b>4</b>	<b>Tax expense</b>				
	- Current tax	51.22	27.41	47.24	220.00
	- Deferred tax	18.75	29.89	28.85	84.21
	<b>Total tax expense (4)</b>	<b>69.97</b>	<b>57.30</b>	<b>76.09</b>	<b>304.21</b>
<b>5</b>	<b>Profit for the period / year (3-4)</b>	<b>202.95</b>	<b>171.25</b>	<b>223.36</b>	<b>894.70</b>
<b>6</b>	<b>Other comprehensive income (OCI)</b>				
	(i) Items that will not be reclassified to profit or loss	(3.64)	0.78	(0.99)	(2.98)
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.92	(0.20)	0.25	0.76
	<b>Total other comprehensive (loss)/ income (net of tax)</b>	<b>(2.72)</b>	<b>0.58</b>	<b>(0.74)</b>	<b>(2.22)</b>
<b>7</b>	<b>Total comprehensive income for the period / year (5+6)</b>	<b>200.23</b>	<b>171.83</b>	<b>222.62</b>	<b>892.48</b>
<b>8</b>	<b>Paid-up equity share capital (face value ₹ 10 per share)</b>	<b>572.25</b>	<b>572.25</b>	<b>572.25</b>	<b>572.25</b>
<b>9</b>	<b>Other equity</b>				<b>7,557.40</b>
<b>10</b>	<b>Basic and diluted earnings per share in ₹ (not annualised for the quarters)</b>	<b>3.55</b>	<b>2.99</b>	<b>3.90</b>	<b>15.63</b>

See accompanying notes to the unaudited standalone financial results



**Innova Captab Limited (CIN: L24246MH2005PLC150371)**

**Notes :**

- 1 The above standalone financial results of Innova Captab Limited ("the Company") have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 ("the act") read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended. The results for the quarter ended 30 June 2025 are available on the Company's website i.e. [www.innovacaptab.com](http://www.innovacaptab.com) under investor information section and on the stock exchange website i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).
- 2 The above standalone financial results have been reviewed and recommended by Audit Committee at its meeting held on 07 August 2025. The Board of Directors at their meeting held on 07 August 2025 have approved the above results and taken them on record. The statutory auditors of the Company have expressed an unmodified review conclusion on the standalone financial results for the quarter ended 30 June 2025.
- 3 The Company has only one reportable segment i.e. "Drugs and pharmaceutical products" as per Ind-AS 108 "Operating Segments" specified under section 133 of the Companies Act, 2013. Accordingly, the disclosures as per the listing agreement are not applicable to the group.
- 4 The figures of the last quarter ended 31 March 2025, as reported in these standalone financial results, are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit.

For and on behalf of the Board of Directors of  
**Innova Captab Limited**



**Vinay Lohariwala**  
Managing Director  
DIN: 00144700



**Lokesh Bhasin**  
Chief Financial Officer

Place: Panchkula  
Date: 07 August 2025

